Colfax Corporation (CFX)
(Delayed Data from NYSE)
$30.27 USD
+0.52 (1.75%)
Updated May 3, 2019 04:02 PM ET
After-Market: $30.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$30.27 USD
+0.52 (1.75%)
Updated May 3, 2019 04:02 PM ET
After-Market: $30.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Colfax (CFX) Moves 5.8% Higher: Will This Strength Last?
by Zacks Equity Research
Colfax (CFX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Colfax (CFX) Q4 Earnings Top Estimates, 2021 View Impressive
by Zacks Equity Research
Colfax's (CFX) Q4 earnings decrease year over year, reflecting the impacts of weak sales generation and a decline in margins. For 2021, it anticipates y/y revenue and earnings growth.
Colfax (CFX) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Colfax (CFX) delivered earnings and revenue surprises of 4.08% and -0.25%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Colfax's (CFX) Unit Closes Buyout of Trilliant Surgical
by Zacks Equity Research
Colfax (CFX) arm DJO closes buyout of Trilliant Surgical, which will boost its product offerings and growth prospects in the foot and ankle surgery market.
5 Industrial Stocks Near 52-Week Highs That Can Scale Higher
by Madhurima Das
The industrial sector is gearing up for growth in 2021. ParkerHannifin (PH), Fortune Brands (FBHS), Reliance Steel (RS), Rexnord (RXN) and Colfax (CFX) are performing well and are set to grow.
Is Colfax (CFX) a Profitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if Colfax (CFX) stock is a good choice for value-oriented investors right now from multiple angles.
Is Colfax (CFX) a Profitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if Colfax (CFX) stock is a good choice for value-oriented investors right now from multiple angles.
Colfax (CFX) Arm's LiteCure Buyout to Boost Product Portfolio
by Zacks Equity Research
Colfax's (CFX) acquisition of LiteCure will create strong growth opportunities for DJO in the physical therapy and rehabilitation market.
Colfax (CFX) to Gain From Products & Buyouts Amid Pandemic Woes
by Zacks Equity Research
Colfax's (CFX) product launches, exposure in multiple markets and gains from buyouts to prove beneficial. However, the pandemic-led challenges and lower selling days remain concerning for Q4.
Colfax (CFX) Arm DJO Acquires Stryker's Extremity Products
by Zacks Equity Research
Colfax (CFX) arm DJO closes buyout of products/system related to ankle replacement and finger arthroplasty from Stryker, which will boost its product offerings in the reconstructive products space.
Colfax (CFX) Q3 Earnings Beat Estimates, Fall Y/Y on Sales
by Zacks Equity Research
Colfax's (CFX) Q3 earnings reflect the impacts of poor product demand due to the pandemic, forex woes and a fall in margin. For Q4, it predicts a sequential rise in sales and earnings.
Colfax (CFX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Colfax (CFX) delivered earnings and revenue surprises of 2.50% and 6.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Colfax (CFX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Parker-Hannifin Gains From Acquisitions Amid Pandemic Scare
by Zacks Equity Research
Parker-Hannifin (PH) is likely to benefit from strength across its end markets and acquired assets. The coronavirus outbreak-led market downturn and high debt level pose concerns.
Reasons Why it is Worth Investing in Colfax (CFX) Stock Now
by Zacks Equity Research
Colfax (CFX) to benefit from growth opportunities in the Fabrication Technology and Medical Technology segments. Also, business in multiple end markets and cost-reduction actions are other tailwinds.
EnPro (NPO) Shares Gain 20% in 3 Months: What's Driving It?
by Zacks Equity Research
EnPro (NPO) benefits from its focus on restructuring portfolio, expertise in material science, cost-management actions and other growth-oriented initiatives.
Graco (GGG) Shares Gain 29% in 3 Months: What's Driving It?
by Zacks Equity Research
Graco (GGG), with a 29% rise in shares in the past three months, benefits from a solid product portfolio, product launches and the reviving U.S. manufacturing activities.
IDEX's Diversified Businesses & Buyouts to Aid Amid Pandemic
by Zacks Equity Research
IDEX's (IEX) diversified product offerings, presence in multiple markets, acquired assets and cost-saving measures might aid performances in the quarters ahead. The pandemic-led headwinds persist.
Colfax's Products & Cost-Saving Actions to Aid Amid Pandemic
by Zacks Equity Research
Colfax's (CFX) focus on innovation and product launches along with cost-saving measures might aid performances in the quarters ahead. Adversities caused by the pandemic and high debts are concerning.
Colfax (CFX) Up 6.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Colfax (CFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Colfax (CFX) Tops Q2 Earnings Estimates, Gives Impressive View
by Zacks Equity Research
Colfax's (CFX) Q2 results reflect the adverse impacts of the pandemic on product demand and forex woes. It predicts generating sequentially higher profits and positive cash flow in Q3.
Colfax (CFX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Colfax (CFX) delivered earnings and revenue surprises of 50.00% and 2.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Colfax (CFX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cintas (CTAS) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Cintas' (CTAS) fiscal Q4 performance is expected to have gained from an expanded product portfolio and the G&K Services buyout despite the pandemic-led market downturn.
Allegion (ALLE) to Post Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Allegion's (ALLE) Q2 earnings are expected to have gained from strength in residential and non-residential businesses. The pandemic-led market downturn and forex woes might have been dragging.